Asa Henin

Special Counsel
Full contact info

Experience

Insys Therapeutics IPO

May 9, 2013

Cooley advised Insys Therapeutics on its initial public offering. Insys Therapeutics, now trading on the Nasdaq Stock Market under the symbol "INSY," is an Arizona-based commercial-stage specialty pharmaceutical company. Insys develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products.

Related contacts

Charlie Kim
Partner, San Diego
Matt Browne
Partner, San Diego
Asa Henin
Special Counsel, San Diego
Terren O'Connor
Associate, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Megan Arthur Schilling
Partner, San Diego

Related Practices & Industries

Synthorx: $63 Million Series C Financing

April 30, 2018

Synthorx, a developer of protein therapeutics, in its $63 million Series C financing.

Related contacts

Ken Rollins
Partner in Charge – San Diego, San Diego
Asa Henin
Special Counsel, San Diego

HTG Completes its Initial Public Offering

May 20, 2015

Cooley advised HTG Molecular Diagnostics on its initial public offering. HTG is a commercial stage company that develops and markets a novel technology platform to facilitate the routine use of complex molecular profiling. The company trades on the Nasdaq Global Market under the symbol "HTGM."

Related contacts

Steve Przesmicki
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Todd Gluth
Partner, San Diego
Wade Andrews
Associate, San Diego
Asa Henin
Special Counsel, San Diego
Phil Mitchell
Partner, New York
Megan Arthur Schilling
Partner, San Diego

Related Practices & Industries

Websense $1 Billion Acquisition by Vista Equity

May 22, 2013

San Diego – Cooley represented Websense in its approximately $1 billion acquisition by Vista Equity Partners. Websense is a global leader in protecting organizations from the latest cyber attacks and data theft, and Vista is a leading private equity firm focused on investments in software, data and technology-enabled businesses.

Under the terms of the agreement, Websense will become a privately held company. Its senior management is expected to continue working with the San Diego-based company.

Related contacts

Barbara Borden
Partner, San Diego
Alfred Browne
Partner, Boston
Asa Henin
Special Counsel, San Diego
Thomas Welk
Senior Counsel, San Diego
Michael Tollini
Partner, Washington, DC

Allogene Therapeutics – $372.6 Million IPO

October 10, 2018

Cooley advised Allogene Therapeutics, Inc. on its $372.6 million initial public offering of 20,700,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 2,700,000 shares. Partners Charles Bair and Charlie Kim led the Cooley team advising Allogene Therapeutics.

Goldman Sachs, J.P. Morgan Securities, Cowen and Jefferies acted as joint book-running managers for the offering.

Allogene Therapeutics is a clinical stage immuno-oncology company developing allogeneic T cell therapies for the treatment of cancer. The company’s shares now trade on the Nasdaq Global Select Market under the symbol “ALLO.”

Related contacts

Charles Bair
Partner, San Diego
Charlie Kim
Partner, San Diego
Asa Henin
Special Counsel, San Diego
Carlos Ramirez
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Madhuri Roy
Partner, Palo Alto

Related Practices & Industries

View more

Admissions and credentials

California

Rankings and accolades

CALI Awards in Corporations and Securities Regulation, Recipient

Memberships and affiliations

State Bar of California